Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.01 2.89 1.01 1.58
Net Debt/EBITDA
1.24 2.65 0.93 1.58
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.51) (2.86) (4.61) (3.93)
Book value per Share
2.71 8.66 9.52 10.85
Free Cash Flow
(4.15) (2.27) (1.16) (1.29)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates